Please login to create your UC TechAlerts.
Request a new password for
Required
Methods for Preparing Ergoline Analogs
Researchers at the University of California, Davis have developed methods to create ergoline analogs that promote neuronal growth without hallucinogenic effects.
Isotryptamine Tetracycles for Treating Brain Disorders
Researchers at the University of California, Davis have developed a technology for the treatment of neuropsychiatric and neurological diseases with compounds that enhance neural plasticity without the hallucinogenic effects.
Riluzole Derivatives Inhibit Neuronal Activity-Regulated Glutamine Transport
Researchers at Louisiana State University, New Orleans and the University of California, Davis have developed neuroprotective compounds that inhibit glutamine transport to reduce excitotoxic glutamate release, offering treatment for neurodegenerative diseases.
Iboga Entactogens
Researchers at the University of California, Davis have developed ibogaine-related compounds that promote neural plasticity and treat neuropsychiatric and neurological disorders.
Combinations of Psychoplastogens and DYRK1A Inhibitors
Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.
Generation of Novel Biotherapeutic (UCD3R) to Repair, Restore and Regenerate Epithelial and Neuronal Systems
Researchers at the University of California, Davis have developed a novel hybrid microbial-derived oxylipin and endocannabinoid-like molecule designed to enhance gut and brain health by improving barrier integrity, reducing inflammation, and providing neuroprotection.
Engineered Phosphite Dehydrogenases for Recycling Orthogonal Noncanonical Cofactors
Engineered phosphite dehydrogenases enable efficient recycling of noncanonical redox cofactors for sustainable biomanufacturing.
Prion Cell Assays for Differentiating α-Synuclein Strains in Synucleinopathies to Advance Neurodegenerative Diagnostics and Treatments
Brief description not available
CRISPR-Based iPSC Drug Discovery Platform: Targeting GNAS-Driven Disorders for Precision Medicine
SFK Covalent Protein Genetic Engineering Platform: Unlocking Potent Therapeutics for Undruggable Targets
A Fluorescent-Labeled Phage Display Platform: RAPID and BIAS Technologies Transform Antibody Discovery for Therapeutic Development
Novel Small GTPase Inhibition Platform: Chemical Genetic Switch II Pocket Inhibitors Targeting Ras, Rho, Rab, and Roc GTPases for Therapeutic Applications in Cancer, CNS Disorders, and Beyond
RocASO: A Breakthrough Platform to Silence Undruggable RNA Targets and Transform Therapeutics
Cell Type-Selective, Potent Signaling Pathway Modulation Using A Guide-Effector Bispecific Design
Manipulation Of Internalization Property Of Cell Surface Molecules Using A Guide-Effector Bispecific Design
Immune Impact Of Cyclic STAT3 Decoy Therapy
Covalent Chemical Inhibitors Of The Oncoprotein K-Ras (G12R)
Discovery Of Kras G12c Inhibitor-Specific Antibodies For Oncogene-Specific Chemically-Directed Immune Targeting
Antibody-Fusion Degraders For Targeted Degradation Of Protein Aggreagates And Organelles Via Autophagy
Sustainable Synthesis: Advanced C(sp³)–N Bonding for Precision Molecule Development Across Industries
Inhibitors Of P90 Rsk
CAPTaINs: Capped And Protected Targeted Immunoproteasome N-End Degrons
CAPTaINs provide a novel, selective, and stable method for selective degradation of protein targets.
Anti-Cxcr6 Treatment For Myocarditis
Optimization Of Lead Small Molecule Inhibitors Of Taspase1 For Cancer Therapeutics